Vertex Articles
Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head
8 April 2013
First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe
20 December 2012
Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C
2 November 2012
FDA warns on possible cataract risk with Vertex' Kalydeco
31 August 2012
Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market
7 June 2012
Vertex slumps as firm revises Kalydeco data
30 May 2012
2011 financial briefs for Alkermes, Allergan, Gilead and Vertex
3 February 2012
FDA approves combo diabetes drug Jentadueto and Kalydeco
1 February 2012
Germany’s IQWiG sees added benefits for Incivo
24 January 2012
Vertex plans for Kalydeco launch
9 January 2012
Vertex updates on US and EU Kalydeco filings; to get new CEO
16 December 2011
Vertex’ Incivek set to break record for fastest product launch
8 November 2011
Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice
9 October 2011
Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C
21 September 2011
Most US clinicians plan to prescribe Incivek and Victrelis for treatment-naive hep C patients
5 July 2011
Alios BioPharma licenses two nucleotide drug candidates to Vertex for up to $1.5 billion
15 June 2011
Merck & Co’s Victrelis and Vertex’ telaprivir get unanimous backing from FDA advisory panel for chronic hep C
29 April 2011
Vertex maintains 2010 outlook, reveals launch plan for hep C drug telaprevir and progress of other programs
11 January 2011
Liver disease meeting hears updates on Merck & Co’s boceprevir, Boehringer Ingelheim’s HCV combo, Vertex’ telaprevir and Gilead’s Viread
2 November 2010
Vertex Pharma reports findings from Ph III telaprevir study, showing no benefit in longer treatment duration
12 August 2010
75% of treatment-naive chronic hepatitis C patients achieve SVR with Vertex’ telaprevir in Ph III trial
27 May 2010
New findings with Vertex/J&J’s telaprevir bode well for hard to treat hepatitis C patients
12 April 2010
Showing 1-42 of 42 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
